EDUCATION PRACTICE. Cirrhosis With Refractory Ascites: Serial Large Volume Paracentesis, TIPS, or Transplantation?
|
|
- Beverly Wiggins
- 6 years ago
- Views:
Transcription
1 CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2011;9: EDUCATION PRACTICE Cirrhosis With Refractory Ascites: Serial Large Volume Paracentesis, TIPS, or Transplantation? VANDANA KHUNGAR* and SAMMY SAAB*, Departments of *Medicine, and Surgery, David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, California This article has an accompanying continuing medical education activity on page e122. Learning Objectives At the end of this activity the successful learner will know the diagnostic criteria for refractory ascites, the concept of transient refractoriness, and the clinical algorithm for management of refractory ascites. See related article, Bhogal HK and Sanyal AJ, on page 936 in this issue of CGH. A Clinical Scenario 59-year-old gentleman with cirrhosis from hepatitis C and alcohol was evaluated for suspected refractory ascites. He complained of dyspnea, abdominal distension, and loss of muscle mass. He was treated with furosemide 80 mg and spironolactone 200 mg once daily. We replaced spironolactone with amiloride because of tender gynecomastia. Despite the use of diuretics, he complained of worsening ascites and required weekly or twice weekly paracentesis. He claimed strict adherence toa2gsodium diet. The patient had an episode of encephalopathy in the past in the context of an esophageal variceal bleed. He is cachectic on physical examination, with temporal and peripheral muscle wasting. His vitals are: blood pressure 125/ 87, pulse 87 and regular, height 73 inches, and weight 185 pounds. Examinations of his thyroid, heart, and lungs are normal. His abdomen is distended with moderate ascites. Superficial collateral vessels are present on his abdomen. The liver and spleen edge are not palpable because of the large amount of ascites. The skin examination is also remarkable for diffuse spider angiomas across the chest and palmar erythema. His laboratory blood work is remarkable for a serum creatinine of 1.1 g/dl, total bilirubin 2.3 g/dl, platelet count 59,000/mL, albumin 2.4 g/dl, serum sodium 131 meq/l, 24-hour urine sodium 70 mmol/l. He had been using spontaneous bacterial peritonitis (SBP) prophylaxis at home for low protein ascites (ascites protein 0.7 g/dl). As an outpatient, he underwent 6 L paracentesis approximately every 2 weeks for 4 weeks. While in the hospital, he is restricted to a monitored 2 g sodium diet (80 mmol/l per day) and continued to accumulate ascites, gaining approximately 0.2 kg daily. The Problem Ascites refers to the accumulation of free fluid in the peritoneum. The most common reason for ascites in the developed world is cirrhosis. Ascites generally responds to both salt restriction and the use of diuretics. It is associated with a poor quality of life, risk of infections, renal failure, umbilical hernia, malnutrition, muscle wasting, and increased mortality. In patients with ascites, 1- and 5-year survival without liver transplantation is 85% and 56%, respectively. Ascites is occasionally refractory despite salt restriction and the use of diuretics. Defining refractory ascites accurately is critical because ascites is often deemed refractory before truly fitting criteria. Ascites may be suboptimally treated or more aggressive interventions prematurely implemented. The importance of taking a history regarding concomitant medication use and compliance cannot be overstated. The clinical impact of refractory ascites is that it is associated with increased mortality. For instance, 2-year survival in patients with diuretic-resistant ascites is approximately 25%. The International Ascites Club Definition Refractory ascites is defined as either: (1) diuretic-resistant ascites ascites that cannot be mobilized or the early recurrence of which cannot be prevented because of a lack of response to dietary sodium restriction and intensive diuretic treatment; or (2) diuretic intractable ascites ascites that cannot be mobilized or the early recurrence of which cannot be prevented because of the development of diuretic-induced complications that preclude the use of an effective diuretic dosage. The diagnostic criteria for refractory ascites is shown in Table 1. Management Strategies and Supporting Evidence Ascites becomes refractory in between 5% and 10% of patients with ascites. Transient or apparent refractoriness to diuretic therapy must be ruled out. Transient refractoriness of ascites can occur with renal impairment from other iatrogenic causes or concurrent, reversible complications. Common rea- Abbreviations used in this paper: AASLD, American Association for the Study of Liver Diseases; EASL, European Association for the Study of Liver Diseases; HRS, hepatorenal syndrome; LVP, large volume paracentesis; MELD, model for end-stage liver disease; TIPS, transjugular intrahepatic portosystemic shunt by the AGA Institute /$36.00 doi: /j.cgh
2 932 KHUNGAR AND SAAB CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 9, No. 11 Table 1. Revised Diagnostic Criteria of Refractory Ascites (International Ascites Club) 1. Treatment duration: patients must be on intensive diuretic therapy (spironolactone 400 mg by mouth daily and furosemide 160 mg by mouth daily) for at least 1 week and on a sodium restricted diet of less than 90 mmol/l per day or 5.2 g of salt (NaCl) per day. 2. Lack of response: mean weight loss of 0.8 kg over 4 days and urinary sodium output less than the sodium intake. 3. Early ascites recurrence: reappearance of grade 2 or 3 ascites within 4 weeks of initial mobilization. 4. Diuretic-induced complications a. Diuretic-induced hepatic encephalopathy: development of encephalopathy in the absence of any other precipitating factor. b. Diuretic-induced renal impairment: increase of serum creatinine by 100% to a value 2 mg/dl in patients with ascites responding to diuretics. c. Diuretic-induced hyponatremia: decrease of serum sodium by 10 mmol/l to a serum sodium of 125 mmol/l. d. Diuretic-induced hypo- or hyperkalemia: change in serum potassium to 3 mmol/l or 6 mmol/l despite appropriate measures. sons for transient refractoriness are dietary indiscretion or diuretic prescription lapses. Other causes of transient refractoriness include nonsteroidal anti-inflammatory drug (NSAID) use, administration of angiotensin I-converting-enzyme inhibitors or angiotensin receptor antagonists, or, the administration of nephrotoxic medications. If needed, low sodium dietary compliance can be confirmed by measuring the 24-hour urinary sodium excretion. A patient on a 2 g sodium diet ingests 88 mmol/l of sodium daily, excretes 10 mmol/l in nonurinary loss and should excrete 78 mmol/l in the urine in 24 hours. Patients who gain weight despite excreting more than 78 mmol/l sodium per day are not compliant with the diet. If a patient with a serum sodium concentration of 140 mmol/l consumes 150 mmol/l sodium daily, he would have a positive sodium balance of 72 mmol/l per day or approximately 0.44 kg. A formula to calculate the expected weight gain on a2gna diet is as follows: (patient s sodium intake in mmol/l 10 mmol/l nonurinary loss 78 mmol/l urinary loss)/140 mmol/l kg weight gain. Paracentesis Paracentesis with albumin is the treatment of choice for refractory ascites, according to guidelines from the European Association for the Study of Liver Diseases (EASL) and the American Association for the Study of Liver Diseases (AASLD). The procedure should preferably be performed in a hospital setting but can be performed safely in the treating provider s office. The advantages of paracentesis are that it can be both diagnostic and therapeutic. Paracentesis can provide immediate relief from dyspnea and abdominal distension. As a diagnostic tool, the paracentesis allows for measurement of cell count to assess for peritonitis. When compared with standard diuretic therapy, large volume paracentesis (LVP) with intravenous (IV) albumin infusion is more effective and is associated with fewer complications. Even patients with no urine sodium excretion can have control of their ascites with biweekly paracentesis. If compliant with a low sodium diet, a patient consumes 88 mmol/l of sodium daily, excretes 10 mmol/l per day in nonurinary losses and excretes no urinary sodium, retaining 78 mmol/l per day. A6Lparacentesis removes 780 mmol/l or approximately 10 days of retained sodium and a 10 L paracentesis removes 17 days of retained sodium (1300 mmol/l) in patients with no urinary sodium excretion. Most studies on paracentesis excluded patients with spontaneous bacterial peritonitis, elevated serum creatinine ( 3 mg/ dl), severe hepatic encephalopathy, severe thrombocytopenia, hypotension, or severe jaundice, but there is no clear evidence that these conditions should be considered major contraindications to paracentesis. Although patients with cirrhosis have coagulopathy and thrombocytopenia, significant peritoneal bleeding during paracentesis is approximately 0.5% to 1%. Thus, fresh frozen plasma or platelet transfusions are not recommended as standard procedure. We generally prefer performing a paracentesis at the patient s left lower quadrant in the office. Ultrasound-guided paracentesis is helpful in patients with ascites found in compartments. Large volume paracentesis should be avoided in patients with disseminated intravascular coagulation. Transjugular Intrahepatic Portosystemic Shunt (TIPS) A TIPS functions as a side-to-side portacaval shunt, and generally lowers intrahepatic portal pressure. As a result of portal pressure normalization, manifestations of portal hypertension such as ascites and varices significantly improve. Moreover, nutritional status and muscle wasting generally improve. In contrast, muscle wasting continues with LVP, likely because protein is removed in the ascitic fluid with LVP. Large volume paracenteses can be inconvenient and time-consuming for both patients and physicians. Post-TIPS patients must still remain on a low sodium diet as the decrease in sinusoidal portal hypertension post-tips results in a very slow increase in urinary sodium excretion of approximately 100 meq per day at 12 months postprocedure. The results of meta-analyses comparing TIPS with LVP indicate that TIPS is associated with better control of ascites, improved renal function, better nutritional status, and a trend toward increased survival. However, the studies are limited by the heterogeneity of the populations, varied definitions of refractory ascites, and the use of bare metal stents. TIPS stenosis can occur in up to 70% of patients with a bare stent in the first year. Thus, bare stents should not be used. Newer polytetrafluoroethylene (PTFE)-covered stents reduce this complication. New or worsening encephalopathy occurs in 20% to 30% of patients after TIPS. Heart failure, renal failure, and liver failure have been reported after TIPS. TIPS should be avoided in patients with recurrent hepatic encephalopathy. Heart failure and active infections are absolute contraindications to TIPS. TIPS in patients with intrahepatic malignancy can cause dissemination of the tumor. Patients must have a patent portal vein and no structural abnormalities such as multiple hepatic cysts.
3 November 2011 CIRRHOSIS WITH REFRACTORY ASCITES TREATMENT 933 Peritoneovenous Shunt Peritoneovenous shunt (LeVeen or Denver) was used in the 1970s and was shown to decrease duration and number of hospitalizations as well as dose of diuretics. Because of poor long-term patency, complications and lack of survival advantage compared with medical therapy, peritoneovenous shunts are almost never performed for ascites today. Shunting should now be reserved for patients who are not candidates for transplant or TIPS and are not candidates for multiple LVPs because of surgical scars or distance from a medical facility with the ability to do LVPs. If surgical scars are associated with loculated ascites, peritoneovenous shunt will not be effective. Orthotopic Liver Transplantation Liver transplantation is the ultimate treatment of advanced liver disease and its complications. However, the current organ allocation system, using the model for end-stage liver disease (MELD) score, does not consider manifestations of portal hypertension such as ascites. The addition of sodium to the MELD score, perhaps a surrogate marker of ascites severity and mortality, improves the accuracy in predicting survival particularly in patients with low MELD score values. Some United Network of Organ Sharing (UNOS) liver transplant regions recognize that the MELD score may not accurately predict survival in patients with refractory ascites. As a result, some United Network for Organ Sharing regions allow MELD exceptions in patients who meet specific criteria. Areas of Uncertainty There are several areas of uncertainty in the treatment of refractory ascites. For instance, EASL guidelines suggest the use of colloid replacement after paracentesis but the implementation of these guidelines in practice is not universal. The argument for using colloid replacement is to prevent paracentesis-induced circulatory dysfunction (PICD), effective hypovolemia, and renal impairment. Albumin has been shown to help prevent paracentesis-induced circulatory dysfunction when a volume of greater than 5 L of ascites is removed during paracentesis. However, the use of albumin can be cumbersome and costly; for this reason, some clinicians do not routinely administer albumin. Some of the recently published guidelines (including EASL 2010 level IA, and AASLD 2009 IIA, level C), recommend the use of albumin for patients treated with LVP of more than 5 L. One study of 105 patients with tense ascites randomized to albumin (10 g/l fluid removed) versus no albumin after large volume paracentesis showed that the group who did not receive albumin developed more changes in electrolytes, plasma rennin, and serum creatinine. Study protocols have included between 5 and 10 g of albumin per liter of fluid removed. No study to date has compared doses of albumin. In Europe, only a 20% albumin solution is available whereas in the US, 5% and 25% isotonic solutions are available. Infusion of the 5% solution increases sodium load 5 times that of the 25% solution. Some of the controversy surrounding postparacentesis plasma expanders relates to study design in current studies, populations are not diuretic-resistant, survival was not a studyspecific endpoint, and doses are not compared. Nonalbumin plasma expanders such as dextran 70, hydroxyethylstarch, and saline have also been advocated, but have not demonstrated survival advantage. Hydroxethylstarch can fill Kupffer cells and cause portal hypertension even in those without portal hypertension. The amount of ascites removed at paracentesis and the frequency of paracentesis are not readily agreed upon. Even patients with no urinary sodium excretion will have their ascites controlled with paracentesis every 2 weeks. This approach has been proven to be safe and effective in controlled trials. The frequency of paracentesis needed allows the clinician to assess compliance with a low sodium diet. The sodium concentration of ascitic fluid is approximately equivalent to that of plasma in cirrhotic patients with ascites (approximately 130 mmol/l). In a 6 L paracentesis, 780 mmol/l of sodium are removed (130 mmol/l 6L 780 mmol/l) and 1300 mmol/l are removed in a 10 L paracentesis. If a patient has no urinary excretion of sodium and consumes 88 mmol/l of sodium daily, and excretes 10 mmol/l daily in nonurinary losses, they retain 78 mmol/l of sodium. For these patients, a 6 L paracentesis removes 10 days of sodium and 10 L paracentesis removes 17 days of sodium. Patients with a small amount of urinary sodium excretion require paracentesis less frequently. Hyponatremia frequently accompanies refractory ascites, believed to be a result of increased vasopressin release. Currently, the treatment of hyponatremia is indicated when serum sodium is less than 125 meq/l and revolves around fluid restriction. There has been increasing interest in using aquaretics to treat hyponatremia. Aquaretics antagonize the V2 receptors, increasing free water excretion and thus serum sodium concentrations. The results of recent randomized controlled trials (RCTs) demonstrated that oral tolvaptan was superior to placebo in correcting hyponatremia secondary to cirrhosis. A major concern is rapid correction of serum sodium, leading to irreversible central pontine myelinolysis. Because of the need for close electrolyte monitoring, aquaretic treatment must be initiated in the hospital setting. When type 2 hepatorenal syndrome occurs with refractory ascites, it can be controversial whether to proceed to TIPS, large volume paracentesis, or combined liver-kidney transplant. Large volume paracentesis can worsen hepatorenal syndrome (HRS) by increasing plasma renin approximately 1 week after paracentesis. TIPS has been proposed as an alternative to paracentesis as it reduces filtration pressure and increases urinary sodium excretion, urinary volume, and improves plasma creatinine concentration. Plasma renin activity, aldosterone, and noradrenalin concentrations also improve gradually after TIPS, suggesting a positive effect on systemic underfilling. Patients must be considered carefully for TIPS as outlined above and if they are appropriate candidates, this is a viable alternative to LVP for HRS. A recent study addreses the issue of which patients with HRS should receive a dual transplant. A retrospective series of 148 patients by Ruiz et al showed that patients who required hemodialysis for longer than 8 weeks prior to transplant had a better outcome after combined transplantation than after liver transplantation. This study suggested kidney after liver transplantation as an option in patients with HRS and persistent posttransplant renal dysfunction of at least 60 days duration. Another study by Davis et al suggests that orthotopic liver transplant candidates on dialysis for 6 weeks pretransplant receive dual liver-kidney transplants. There is still no consensus though on which patients should receive a dual transplant. It is our institution s practice to consider dual liver/kidney transplantation in patients on hemodialysis for more than 4 weeks.
4 934 KHUNGAR AND SAAB CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 9, No. 11 Figure 1. Suggested approach to the cirrhotic patient with ascites not responsive to diuretics. GI, gastrointestinal; NSAID, nonsteroidal antiinflammatory drug; OLT, orthotopic liver transplant; SBP, spontaneous bacterial peritonitis. Lack of response defined as mean weight loss 0.8 kg over 4 days and urinary sodium output less than sodium intake on intensive diuretic therapy (spironolactone 400 mg by mouth daily and furosemide 160 mg by mouth daily) for at least 1 week and on a sodium restricted diet of 90 mmol/l per day or 5.2 g of salt per day. Refractory ascites defined by the International Ascites Club is either: (1) diuretic resistant ascites ascites that cannot be mobilized or the early recurrence of which cannot be prevented because of a lack of response to dietary sodium restriction and intensive diuretic treatment; or (2) diuretic-intractable ascites ascites that cannot be mobilized or the early recurrence of which cannot be prevented because of the development of diuretic-induced complications that preclude the use of an effective diuretic dosage. Other treatment strategies that are emerging for refractory ascites include the sole use or combination of albumin infusion, midodrine, and subcutaneous octreotide. However, further trials are needed before these experimental therapies can be recommended in routine clinical practice. Society Guidelines Two hepatology associations have published clinical guidelines for the treatment of refractory ascites. The AASLD guidelines on the management of ascites were published in Class I recommendations include: serial LVPs are a treatment option for refractory ascites, postparacentesis albumin infusion is not necessary for a single paracentesis of less than 4 to 5 L, TIPS may be considered in appropriately selected patients who meet criteria similar to those of published randomized trials. The EASL guidelines were published in Repeated LVP with albumin is the first line of therapy for refractory ascites and diuretics should be discon- Table 2. Available Diuretics and Aquaretics for Treatment of Ascites and Hyponatremia Diuretic/aquaretic Usual adult dose (mg) Time to peak effect (h) Duration of action Average wholesale price (30 d; US$) Aldosterone antagonists Spironolactone days Eplerenone days Loop diuretic Furosemide hours Epithelial sodium channel blocker Amiloride hours Aquaretic (vasopressin antagonist) Tolvaptan hours ,000
5 November 2011 CIRRHOSIS WITH REFRACTORY ASCITES TREATMENT 935 tinued in those with refractory ascites who do not excrete 30 mmol/l per day of sodium with diuretic use. Assessment of response of ascites to diuretic therapy and salt restriction should be performed only in stable patients without associated complications such as bleeding or infection. Patients with refractory ascites should be considered for orthotopic liver transplant. TIPS is effective for refractory ascites but is associated with a high risk of hepatic encephalopathy and has not been shown convincingly to improve survival. TIPS should be considered in patients who require very frequent LVP or in whom paracentesis is ineffective because of loculated ascites. TIPS is not recommended in patients with severe liver failure (serum bilirubin 5 mg/dl, international normalized ratio 2, or Child Pugh score 11, current hepatic encephalopathy grade 2 or chronic hepatic encephalopathy), concomitant active infection, progressive renal failure, or severe cardiopulmonary disease. The AASLD and EASL guidelines favor therapies with robust evidence from randomized controlled trials (RCTs). Combining the evidence from the guidelines, an approach to the patient with refractory ascites is presented in Figure 1. Characteristics of the pharmacologic agents available for ascites and hyponatremia are presented in Table 2. Some of the newer experimental therapies as well as covered stents in TIPS which have not undergone extensive evaluation may prove to be superior options for the treatment of refractory ascites. Summary The patient was admitted to the hospital for further evaluation and possible TIPS. On admission, the patient s furosemide and amiloride were continued at previously prescribed doses. Urine sodium was 70 mmol/l on a 90 mmol/l sodium per day diet. A Doppler ultrasound of the abdominal vessels showed patent portal vein, hepatic vein and artery, and inferior vena cava with appropriate direction of flow. With increasing diuretic doses, the patient s creatinine rose from 1.1 to 2.5 mg/dl. His urine output decreased and he was felt to have developed hepatorenal syndrome. On the morning the patient was scheduled for TIPS for his refractory ascites, he was noted to be grossly encephalopathic. His bilirubin increased to 8 mg/dl and his international normalized ratio to 2.7 mg/dl. He underwent a full infectious workup including diagnostic paracentesis and no source of infection was found. A decision was made to forgo TIPS and the patient was listed for orthotopic liver transplantation, which he received 2 months later. Suggested Reading 1. Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009;49: European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53: Salerno F, Guevara M, Bernardi M, et al. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int 2010;30: Senousy BE, Draganov PV. Evaluation and management of patients with refractory ascites. World J Gastroenterol 2009;15: Wong F, Gines P, Watson H, et al. Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol 2010;53: Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010;21: Somsouk M, Kornfield R, Vittinghoff E, et al. Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk. Liver Transplant 2011;17: Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the international ascites club. Hepatology 2003;38: Ginès P, Titó L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988;94: Lacy CF. Drug Information Handbook 2010/2011, 19th ed, Hudson, OH: Lexi-Comp, Davis CL, Feng S, Sung R, et al. Simultaneous liver-kidney transplantation: evaluation to decision making. Am J Transplant 2007; 7: Ruiz R, Barri YM, Jennings LW, et al. Hepatorenal syndrome: a proposal for kidney after liver transplantation (KALT). Liver Transplant 2007;13: Reprint requests Address requests for reprints to: Sammy Saab, MD, MPH, AGAF, Pfleger Liver Institute, UCLA Medical Center, 200 Medical Plaza, Suite 214, Los Angeles, California ssaab@mednet.ucla. edu; fax: (310) Acknowledgments The authors thank Noel Ayoub for his assistance with figure construction. Conflicts of interest The authors disclose no conflicts.
Management of Cirrhotic Complications Uncontrolled Ascites. Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University
Management of Cirrhotic Complications Uncontrolled Ascites Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University Topic Definition, pathogenesis Current therapeutic options Experimental treatments
More informationEDUCATION PRACTICE. Management of Refractory Ascites. Clinical Scenario. The Problem
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2005;3:1187 1191 EDUCATION PRACTICE Management of Refractory Ascites ANDRÉS CÁRDENAS and PERE GINÈS Liver Unit, Institute of Digestive Diseases, Hospital Clínic,
More informationInitial approach to ascites
Ascites: Filling and Draining the Water Balloon Common Pathogenesis in Refractory Ascites, Hyponatremia, and Cirrhosis intrahepatic resistance sinusoidal portal hypertension Splanchnic vasodilation (effective
More informationManagement of Ascites and Hepatorenal Syndrome. Florence Wong University of Toronto. June 4, /16/ Gore & Associates: Consultancy
Management of Ascites and Hepatorenal Syndrome Florence Wong University of Toronto June 4, 2016 6/16/2016 1 Disclosures Gore & Associates: Consultancy Sequana Medical: Research Funding Mallinckrodt Pharmaceutical:
More informationThe Management of Ascites & Hepatorenal Syndrome. Florence Wong University of Toronto. Falk Symposium March 14, 2008
The Management of Ascites & Hepatorenal Syndrome Florence Wong University of Toronto Falk Symposium March 14, 2008 Management of Ascites Sodium Restriction Mandatory at all stages of ascites in order to
More informationAscites Management. Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology
Ascites Management Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Disclosure 1. The speaker Atif Zaman, MD MPH have no relevant
More informationJOURNAL PRESENTATION. Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013
JOURNAL PRESENTATION Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013 THE COMBINATION OF OCTREOTIDE AND MIDODRINE IS NOT SUPERIOR TO ALBUMIN IN PREVENTING RECURRENCE OF ASCITES AFTER LARGE-VOLUME PARACENTESIS
More informationCirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association
CIRRHOSIS AND PORTAL HYPERTENSION Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association WHAT IS CIRRHOSIS? What is Cirrhosis? DEFINITION OF CIRRHOSIS
More informationHepatorenal syndrome. Jan T. Kielstein Departent of Nephrology Medical School Hannover
Hepatorenal syndrome Jan T. Kielstein Departent of Nephrology Medical School Hannover Hepatorenal Syndrome 1) History of HRS 2) Pathophysiology of HRS 3) Definition of HRS 4) Clinical presentation of HRS
More informationMANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT
MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT Sherona Bau, ACNP The Pfleger Liver Institute 200 UCLA Medical Plaza, Suite 214 Los Angeles, CA 90095 September 30, 2017 I
More informationFrom Sodium Retention to Therapy for Refractory Ascites The Role for New Drugs. Florence Wong University of Toronto. Falk Symposium October 14, 2007
From Sodium Retention to Therapy for Refractory Ascites The Role for New Drugs Florence Wong University of Toronto Falk Symposium October 14, 2007 Sodium Retention in Cirrhosis Occurs as a result of hemodynamic
More informationProf. Mohammad Umar. MBBS, MCPS, FCPS, FACG (USA), FRCP (London), FRCP (Glasgow), FAGA
Prof. Mohammad Umar MBBS, MCPS, FCPS, FACG (USA), FRCP (London), FRCP (Glasgow), FAGA Chairman and Head Department of Medicine Rawalpindi Medical College, Rawalpindi. Consultant Gastroenterologist / Hepatologist
More informationFilippo Schepis, MD Università degli Studi di Modena e Reggio Emilia
Filippo Schepis, MD Università degli Studi di Modena e Reggio Emilia Il sottoscritto dichiara di non aver avuto/di aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione
More informationEASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis
EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis European Association for the Study of the Liver 1 Ascites is the
More informationManagement of Cirrhosis Related Complications
Management of Cirrhosis Related Complications Ke-Qin Hu, MD, FAASLD Professor of Clinical Medicine Director of Hepatology University of California, Irvine Disclosure I have no disclosure related to this
More informationBeta-blockers in cirrhosis: Cons
Beta-blockers in cirrhosis: Cons Eric Trépo MD, PhD Dept. of Gastroenterology. Hepatopancreatology and Digestive Oncology. C.U.B. Hôpital Erasme. Université Libre de Bruxelles. Bruxelles. Belgium Laboratory
More informationNorepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome
Norepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome Disclosure I have no conflicts of interest to disclose Name: Margarita Taburyanskaya Title: PharmD, PGY1 Pharmacy Practice Resident
More informationAscites is the most common complication of cirrhosis and. Natural History of Patients Hospitalized for Management of Cirrhotic Ascites
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:1385 1394 Natural History of Patients Hospitalized for Management of Cirrhotic Ascites RAMON PLANAS,* SILVIA MONTOLIU,* BELEN BALLESTÉ, MONICA RIVERA, MIREIA
More informationTreating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC
Treating patients with end-stage liver disease: Are we ready? Dr. Mino R. Mitri, M.D., C.M., M.Ed., FRCPC mino.mitri@ubc.ca No Conflict of Interest 157 patients 157 patients 6 transplanted Criteria Liver
More informationManagement of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL
Management of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL Terminology Acute decompensation of cirrhosis - stable patient with sudden deterioration Acute-on-chronic liver failure
More informationConflict of interest disclosures. Complications of end stage liver disease. None. The many complications of Cirrhosis. Portal Hypertension.
Complications of end stage liver disease Conflict of interest disclosures None Amir Qamar, MD Instructor of Medicine Brigham and Women s s Hospital Harvard Medical School Boston, MA 02115 The many complications
More informationREVIEW. Ariel W. Aday, M.D.,* Nicole E. Rich, M.D.,* Arjmand R. Mufti, M.D., and Shannan R. Tujios, M.D.
REVIEW CON ( The Window Is Closed ): In Patients With Cirrhosis With Ascites, the Clinical Risks of Nonselective beta-blocker Outweigh the Benefits and Should NOT Be Prescribed Ariel W. Aday, M.D.,* Nicole
More informationControversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate
Controversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate Patrick Northup, MD, FAASLD, FACG Medical Director, Liver Transplantation University of Virginia
More informationChronic Hepatic Disease
Chronic Hepatic Disease 10 th Leading Cause of Death Liver Functions Energy Metabolism Protein Synthesis Solubilization, Transport, and Storage Protects and Clears drugs, damaged cells Causes of Liver
More informationACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis
ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis Guadalupe Garcia-Tsao, M.D., 1 Arun J. Sanyal, M.D., 2 Norman D. Grace,
More informationContraindications. Indications. Complications. Currently TIPS is considered second or third line therapy for:
Contraindications Absolute Relative Primary prevention variceal bleeding HCC if centrally located Active congestive heart failure Obstruction all hepatic veins Thomas D. Boyer, M.D. University of Arizona
More informationAASLD PRACTICE GUIDELINE Management of Adult Patients with Ascites Due to Cirrhosis: Update 2012
AASLD PRACTICE GUIDELINE Management of Adult Patients with Ascites Due to Cirrhosis: Update 2012 Bruce A. Runyon, M.D. Preamble This guideline has been approved by the American Association for the Study
More informationISPUB.COM. Management of Ascites. V Mahesh SOURCE OF SUPPORT DIAGNOSIS OF ASCITES INTRODUCTION CAUSES [,] DIAGNOSTIC TESTS
ISPUB.COM The Internet Journal of Gastroenterology Volume 5 Number 2 Management of Ascites V Mahesh Citation V Mahesh. Management of Ascites. The Internet Journal of Gastroenterology. 2006 Volume 5 Number
More informationHepatorenal syndrome. Jan Jan T. T. Kielstein Departent of of Nephrology Medical School School Hannover
Hepatorenal syndrome Jan Jan T. T. Kielstein Departent of of Nephrology Medical School School Hannover Hepatorenal Syndrome 1) History of HRS 2) Pathophysiology of HRS 3) Definition of HRS 4) Clinical
More informationDenver Shunts vs TIPS for Ascites
Denver Shunts vs TIPS for Ascites Hooman Yarmohammadi MD Assistant Professor of Radiology Interventional Radiology & Image Guided Therapies Memorial Sloan-Kettering Cancer Center, New York, USA Hooman
More informationEtiology of liver cirrhosis
Liver cirrhosis 1 Liver cirrhosis Liver cirrhosis is the progressive replacement of normal hepatic cells by fibrous scar tissue, This scarring is accompanied by the loss of viable hepatocytes, which are
More informationCIRRHOTIC MANAGEMENT
DISCLAIMER: These guidelines were prepared by the Department of Surgical Education, Orlando Regional Medical Center. They are intended to serve as a general statement regarding appropriate patient care
More informationAscites. Matthew Johnson M.D.
Ascites Matthew Johnson M.D. The most common complication of portal hypertension 50% of patients who have compensated cirrhosis develop ascites by 10 years Survival after ascites develops: 1-year: 85%
More informationSign up to receive ATOTW weekly -
HEPATORENAL SYNDROME ANAESTHESIA TUTORIAL OF THE WEEK 240 10 TH SEPTEMBER 2011 Gerry Lynch Rotherham General Hospital Correspondence to gerry.lynch@rothgen.nhs.uk QUESTIONS Before continuing, try to answer
More informationManagement of Chronic Liver Failure/Cirrhosis Complications in Hospitals. By: Dr. Kevin Dolehide
Management of Chronic Liver Failure/Cirrhosis Complications in Hospitals By: Dr. Kevin Dolehide Overview DX Cirrhosis and Prognosis Compensated Decompensated Complications Of Cirrhosis Management Of Complications
More informationJMSCR Vol 05 Issue 11 Page November 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i11.33 Prevalence of Hyponatremia among patients
More informationElevated Creatinine in a Patient With Cirrhosis
REVIEW Elevated Creatinine in a Patient With Cirrhosis Heather L. Klavan, M.D., and Brett E. Fortune, M.D., M.S. Elevation in serum creatinine is a common laboratory finding for patients with cirrhosis
More informationManagement of the Cirrhotic Patient in the ICU
Management of the Cirrhotic Patient in the ICU Peter E. Morris, MD Professor & Chief, Pulmonary, Critical Care and Sleep Medicine University of Kentucky Conflict of Interest Funding US National Institutes
More informationEnd-Stage Liver Disease (ESLD): A Guide for HIV Physicians
Slide 1 of 32 End-Stage Liver Disease (ESLD): A Guide for HIV Physicians Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California
More informationCLINICAL How Should a Hospitalized Patient with Newly Diagnosed Cirrhosis Be Evaluated and Managed?
CLINICAL How Should a Hospitalized Patient with Newly Diagnosed Cirrhosis Be Evaluated and Managed? The Hospitalist. 2016 August;2016(8) Author(s): Raj Sehgal, MD; Joshua Hanson, MD, MPH; Division OF The
More informationSteps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV
Overview of Liver Disease Associated With HCV Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco San Francisco,
More informationThe Use of Albumin for the Prevention of Hepatorenal Syndrome in Patients with Spontaneous Bacterial Peritonitis and Cirrhosis
The Use of Albumin for the Prevention of Hepatorenal Syndrome in Patients with Spontaneous Bacterial Peritonitis and Cirrhosis http://www.funnyjunk.com/funny_pictures/1743659/enlarged/ Daniel Giddings,
More informationVARICEAL BLEEDING. Ram Subramanian MD Hepatology & Critical Care Medical Director of Liver Transplant Emory University, Atlanta.
VARICEAL BLEEDING Ram Subramanian MD Hepatology & Critical Care Medical Director of Liver Transplant Emory University, Atlanta Disclosures: None OUTLINE Pathophysiology of portal hypertension Splanchnic
More informationThe MELD Score in Advanced Liver Disease: Association with Clinical Portal Hypertension and Mortality
The MELD Score in Advanced Liver Disease: Association with Clinical Portal Hypertension and Mortality Sammy Saab, 1,2 Carmen Landaverde, 3 Ayman B Ibrahim, 2 Francisco Durazo, 1,2 Steven Han, 1,2 Hasan
More informationManagement of refractory ascites in cirrhosis: Are we out of date?
Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.4254/wjh.v8.i28.1182 World J Hepatol 2016 October 8; 8(28): 1182-1193 ISSN 1948-5182 (online)
More informationCIRRHOSIS Definition
Cirrhosis Update Robert S. Brown, Jr., MD, MPH Vice Chair, Transitions of Care Interim Chief, Division of Gastroenterology & Hepatology Weill Cornell Medical College CIRRHOSIS Definition Irreversible fibrous
More informationBETA-BLOCKERS IN CIRRHOSIS.PRO.
BETA-BLOCKERS IN CIRRHOSIS.PRO. Angela Puente Sánchez. MD PhD Hepatology Unit. Gastroenterology department Marques de Valdecilla University Hospital. Santander INTRODUCTION. Natural history of cirrhosis
More informationfollowing the last documented transfusion; thereafter, evaluate the residual impairment(s).
Adult Listings 5.01 Category of Impairments, Digestive System 5.02 Gastrointestinal hemorrhaging from any cause, requiring blood transfusion (with or without hospitalization) of at least 2 units of blood
More informationESLD a Guide for HIV Physicians. Marion Peters University of California San Francisco June 2015
ESLD a Guide for HIV Physicians Marion Peters University of California San Francisco June 2015 Disclosures Honararia from Johnson and Johnson Roche Merck Gilead Spouse employee of Hoffman La Roche Natural
More informationPortal hypertension is the main complication of cirrhosis
GASTROENTEROLOGY 2001;120:726 748 Current Management of the Complications of Cirrhosis and Portal Hypertension: Variceal Hemorrhage, Ascites, and Spontaneous Bacterial Peritonitis GUADALUPE GARCIA TSAO
More informationVirtual Mentor American Medical Association Journal of Ethics December 2008, Volume 10, Number 12:
Virtual Mentor American Medical Association Journal of Ethics December 2008, Volume 10, Number 12: 805-809. CLINICAL PEARL Indications for Use of TIPS in Treating Portal Hypertension Elizabeth C. Verna,
More informationAcute Liver Failure. Neil Shah, MD UNC School of Medicine High-Impact Hepatology Saturday, Dec 8 th, 2018
Acute Liver Failure Neil Shah, MD UNC School of Medicine High-Impact Hepatology Saturday, Dec 8 th, 2018 Disclosures None Outline Overview of ALF Management of ALF Diagnosis of ALF Treatments and Support
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our
More informationThe Yellow Patient. Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust
The Yellow Patient Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust there s a yellow patient in bed 40. It s one of yours. Liver Cirrhosis Why.When.What.etc.
More informationHepatorenal Syndrome
Necker Seminars in Nephrology Institut Pasteur Paris, April 22, 2013 Hepatorenal Syndrome Dr. Richard Moreau 1 INSERM U773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, 2 Université Paris Diderot
More informationEvidence-Base Management of Esophageal and Gastric Varices
Evidence-Base Management of Esophageal and Gastric Varices Rino Alvani Gani Hepatobiliary Division Department of Internal Medicine Faculty of Medicine Universitas Indonesia Cipto Mangunkusumo National
More informationTherapy Insight: management of hepatorenal syndrome
Therapy Insight: management of hepatorenal syndrome Andrés Cárdenas and Pere Ginès* SUMMARY Hepatorenal syndrome (HRS), a feared complication of advanced cirrhosis, is characterized by functional renal
More informationDIAGNOSIS AND MANAGEMENT OF DIURETIC RESISTANCE. Jules B. Puschett, M.D.
DIAGNOSIS AND MANAGEMENT OF DIURETIC RESISTANCE Jules B. Puschett, M.D. Diuretic Resistance A clinical circumstance in which patients do not respond to a combination of salt restriction and even large
More informationIV Fluids. I.V. Fluid Osmolarity Composition 0.9% NaCL (Normal Saline Solution, NSS) Uses/Clinical Considerations
IV Fluids When administering IV fluids, the type and amount of fluid may influence patient outcomes. Make sure to understand the differences between fluid products and their effects. Crystalloids Crystalloid
More informationOntario s Adult Referral and Listing Criteria for Liver Transplantation
Ontario s Adult Referral and Listing Criteria for Liver Transplantation Version 3.0 Trillium Gift of Life Network Ontario s Adult Referral & Listing Criteria for Liver Transplantation PATIENT REFERRAL
More informationRENAL DISEASE IN END STAGE LIVER DISEASE
RENAL DISEASE IN END STAGE LIVER DISEASE Mitchell L Shiffman, MD Director Health System Richmond and Newport News, VA Medical Group Good Help to Those in Need Mitchell L Shiffman, MD POTENTIAL CONFLICTS
More informationCare of the Patient With Cirrhosis
REVIEW Care of the Patient With Cirrhosis Anitha Yadav, M.D., and Hugo E. Vargas, M.D. Caring for patients with cirrhosis involves multidisciplinary and timely management of several complications while
More informationCase Report Low-Dose Tolvaptan for the Treatment of Dilutional Hyponatremia in Cirrhosis: A Case Report and Literature Review
Case Reports in Hepatology, Article ID 795261, 4 pages http://dx.doi.org/10.1155/2014/795261 Case Report Low-Dose Tolvaptan for the Treatment of Dilutional Hyponatremia in Cirrhosis: A Case Report and
More informationThe Association Between the Serum Sodium Level and the Severity of Complications in Liver Cirrhosis
ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.2.106 The Association Between the Serum Sodium Level and the Severity of Complications in Liver Cirrhosis Jong Hoon Kim, June Sung Lee, Seuk Hyun Lee, Won Ki
More informationDialyzing challenging patients: Patients with hepato-renal conditions
Dialyzing challenging patients: Patients with hepato-renal conditions Nidyanandh Vadivel MD Medical Director for Living kidney Donor and Pancreas Transplant Programs Swedish Organ Transplant, Seattle Acute
More informationCOMPLICATIONS OF CIRRHOSIS: ASCITES & HEPATIC ENCEPHALOPATHY
COMPLICATIONS OF CIRRHOSIS: ASCITES & HEPATIC ENCEPHALOPATHY DR. ESTER YAGUDAYEVA CLINICAL PHARMACIST HOSPICE PHARMACY SOLUTIONS OBJECTIVES Understand the prognosis of End Stage Liver Disease (ESLD) Identify
More informationPORTAL HYPERTENSION. Tianjin Medical University LIU JIAN
PORTAL HYPERTENSION Tianjin Medical University LIU JIAN DEFINITION Portal hypertension is present if portal venous pressure exceeds 10mmHg (1.3kPa). Normal portal venous pressure is 5 10mmHg (0.7 1.3kPa),
More informationThe Continuum of Care for Advanced Liver Disease: Partnering with the Liver Specialist. K V Speeg, MD, PhD UT Health San Antonio
The Continuum of Care for Advanced Liver Disease: Partnering with the Liver Specialist K V Speeg, MD, PhD UT Health San Antonio Objectives Review staging of liver disease Review consequences of end-stage
More informationManaging Cirrhosis. Cirrhosis of the liver is a progressive, fibrosing. Ascites. By Cameron Ghent, MD, FRCPC. Complications of Cirrhosis
Focus on CME at the University of Western Ontario Managing Cirrhosis By Cameron Ghent, MD, FRCPC Cirrhosis of the liver is a progressive, fibrosing process resulting in nodule formation and microvascular
More informationDiuretic Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Diuretic Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Potassium-sparing diuretics The Ion transport pathways across the luminal and basolateral
More informationLiver failure &portal hypertension
Liver failure &portal hypertension Objectives: by the end of this lecture each student should be able to : Diagnose liver failure (acute or chronic) List the causes of acute liver failure Diagnose and
More informationDISEASE LEVEL MEDICAL EVIDENCE PROTOCOL
DISEASE LEVEL MEDICAL EVIDENCE PROTOCOL 1. This Protocol sets out the medical evidence that must be delivered to the Administrator for proof of Disease Level. It is subject to such further and other Protocols
More informationHepatorenal syndrome a defined entity with a standard treatment?
Hepatorenal syndrome a defined entity with a standard treatment? Falk Symposium 162 Dresden - October 14, 2007 Alexander L. Gerbes Klinikum of the University of Munich Grosshadern Department of Medicine
More informationT herapeutic (that is, total) paracentesis is used in patients
90 LIVER AND BILIARY DISEASE Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by : a randomised pilot study R Moreau, T
More informationDefinition: fibrosis and nodular regeneration resulting from hepatocellular injury
Cirrhosis Understanding the liver: Patterns of LFT Abnormalities - Hepatocellular/Transaminitis: o Ratio of AST: ALT >2:1 ETOH (keep in mind AST is also produced by red cells, heart muscle) o If Aminotransferases
More informationProgram Disclosure. This program is supported by an educational grant from Salix Pharmaceuticals.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship
More informationComplication of Portal Hypertension: should the patients in the waiting list be treated differently?
Wilma Debernardi Venon Gastroepatologia, Az. Osp. San Giovanni Battista ditorino Complication of Portal Hypertension: should the patients in the waiting list be treated differently? Il sottoscritto dichiara
More informationEvaluation Process for Liver Transplant Candidates
Evaluation Process for Liver Transplant Candidates 2 Objectives Identify components of the liver transplant referral to evaluation Describe the role of the liver transplant coordinator Describe selection
More informationDefinition: HPS is a disease process with a triad of: 1- Liver disease. 2- Widespread intrapulmonary vasodilatation. 3- Gas exchange abnormality prese
Hepatopulmonary syndrome (HPS) By Alaa Haseeb, MS.c Definition: HPS is a disease process with a triad of: 1- Liver disease. 2- Widespread intrapulmonary vasodilatation. 3- Gas exchange abnormality presenting
More informationHEPATOrenal Syndrome Type I: Correct Diagnosis = Correct Management
HEPATOrenal Syndrome Type I: Correct Diagnosis = Correct Management Stephen G. M. Wong BSc, BSc(Med), MD, MHSc, FRCPC Associate Professor of Medicine Director, Hepatology Education Section of Hepatology
More informationEsophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph
Esophageal Varices Beta-Blockers or Band Ligation Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph Esophageal Varices Beta-Blockers or Band Ligation? Risk of esophageal variceal
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Accelerated intravascular coagulation and fibrinolysis (AICF) in liver disease, 390 391 Acid suppression in liver disease, 403 404 ACLF.
More informationRISK STRATIFICATION IN CIRRHOSIS: FOCUS ON UMBILICAL HERNIA Sam Hawkins MD PGY5
RISK STRATIFICATION IN CIRRHOSIS: FOCUS ON UMBILICAL HERNIA Sam Hawkins MD PGY5 PATIENT PRESENTATION 73M w/ Hep B Cirrhosis, HTN, DM II Liver disease followed at OSH x2 years (when moved from China), on
More informationGI bleeding in chronic liver disease
GI bleeding in chronic liver disease Stuart McPherson Consultant Hepatologist Liver Unit, Freeman Hospital, Newcastle upon Tyne and Institute of Cellular Medicine, Newcastle University. Case 54 year old
More informationAssociation between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia
doi: 10.2169/internalmedicine.0629-17 Intern Med 57: 2451-2458, 2018 http://internmed.jp ORIGINAL ARTICLE Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients
More informationINCIDENCE OF BACTERIAL INFECTIONS IN CIRRHOSIS
INCIDENCE OF BACTERIAL INFECTIONS IN CIRRHOSIS Yoshida H et al (1993)* Deschenes M et al (1999)** Strauss E et al (1993) Borzio M et al (2002) PATIENTS 1140 140 170 405 INFECTIONS 15.4% 20% 47% 34% * Many
More informationPathophysiology, diagnosis and treatment of ascites in cirrhosis
Annals of hepatology 2002; 1(2): April-June: 72-79 Concise Review Annals of hepatology Pathophysiology, diagnosis and treatment of ascites in cirrhosis Vicente Arroyo 1, M.D. Abstract The mechanism by
More informationAdrenal Insufficiency in Patients with Liver Cirrhosis and Severe Sepsis: Effect on Survival after Treatment with Hydrocortisone ABSTRACT
20 Original Article Adrenal Insufficiency in Patients with Liver Cirrhosis and Severe Sepsis: Effect on Survival after Treatment with Hydrocortisone Pattanasirigool C Prasongsuksan C Settasin S Letrochawalit
More informationLIVER CIRRHOSIS. The liver extracts nutrients from the blood and processes them for later use.
LIVER CIRRHOSIS William Sanchez, M.D. & Jayant A. Talwalkar, M.D., M.P.H. Advanced Liver Disease Study Group Miles and Shirley Fiterman Center for Digestive Diseases Mayo College of Medicine Rochester,
More informationReview Article Management of Renal Failure and Ascites in Patients with Cirrhosis
SAGE-Hindawi Access to Research International Journal of Hepatology Volume 2011, Article ID 790232, 7 pages doi:10.4061/2011/790232 Review Article Management of Renal Failure and Ascites in Patients with
More informationCOMPOSITION. A film coated tablet contains. Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar (Film coated tablets) Irbesartan
Rotazar (Film coated tablets) Irbesartan Rotazar 75 mg, 150 mg, 300 mg COMPOSITION A film coated tablet contains Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar 75 mg, 150 mg, 300 mg PHARMACOLOGICAL
More informationIntravenous Furosemide and Human Albumin for Treatment of Cirrhotic Ascites: Useful or Harmful?
Ibnosina J Med BS 83 ARTICLE Intravenous Furosemide and Human Albumin for Treatment of Cirrhotic Ascites: Useful or Harmful? Faisal O. Abubakor, Hind I. Fallatah, Hisham O. Akbar Department of Medicine,
More informationOver- and underfill: not all nephrotic states are equal. Detlef Bockenhauer
Over- and underfill: not all nephrotic states are equal Detlef Bockenhauer Objectives Review pathophysiology of oedema: undervs overfill Treatment options The clinical setting: case 1 A6-y old girl with
More informationAASLD PRACTICE GUIDELINE. The Role of Transjugular Intrahepatic Portosystemic Shunt in the Management of Portal Hypertension. Preamble.
AASLD PRACTICE GUIDELINE The Role of Transjugular Intrahepatic Portosystemic Shunt in the Management of Portal Hypertension Thomas D. Boyer 1 and Ziv J. Haskal 2 Preamble The recommendations in this article
More informationAscites, a New Cause for Bilateral Hydronephrosis: Case Report
Case Study TheScientificWorldJOURNAL (2009) 9, 1035 1039 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2009.112 Ascites, a New Cause for Bilateral Hydronephrosis: Case Report D. Jain*, S. Dorairajan, and
More informationDiagnosis and Management of Ascites
Hepatitis C Online PDF created July 4, 2018, 6:39 pm Diagnosis and Management of Ascites This is a PDF version of the following document: Module 3: Management of Cirrhosis-Related Complications Lesson
More informationDRAFT. Angiography: Transjugular Intrahepatic Portosystemic Shunt (TIPS) What to expect. What is a transjugular intrahepatic portosystemic shunt?
UW MEDICINE PATIENT EDUCATION Angiography: Transjugular Intrahepatic Portosystemic Shunt (TIPS) What to expect This handout explains a transjugular intrahepatic portosystemic shunt and what to expect when
More informationEvaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA
Evaluating HIV Patient for Liver Transplantation Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Slide 2 ESLD and HIV Liver disease has become a major cause of death
More informationHyponatremia as a Cardiovascular Biomarker
Hyponatremia as a Cardiovascular Biomarker Uri Elkayam, MD Professor of Medicine University of Southern California Keck School of Medicine elkayam@usc.edu Disclosure Research grant from Otsuka for the
More information